NewAmsterdam Pharma Co. NV (NAMS)
27.35
+0.01
(+0.04%)
USD |
NASDAQ |
Aug 26, 13:32
NewAmsterdam Pharma Net Income (Quarterly) : -64.14M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -64.14M |
| March 31, 2026 | -48.44M |
| December 31, 2025 | -74.92M |
| September 30, 2025 | -72.00M |
| June 30, 2025 | -17.36M |
| March 31, 2025 | -39.53M |
| December 31, 2024 | -92.18M |
| September 30, 2024 | -16.65M |
| June 30, 2024 | -39.01M |
| Date | Value |
|---|---|
| March 31, 2024 | -93.77M |
| September 30, 2022 | -4.780M |
| June 30, 2022 | -1.173M |
| March 31, 2022 | 1.385M |
| December 31, 2021 | 0.9297M |
| September 30, 2021 | 1.73M |
| June 30, 2021 | -1.299M |
| March 31, 2021 | 2.818M |
| December 31, 2020 | 0.0415M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ProQR Therapeutics NV | -10.15M |
| Pharming Group NV | 1.598M |
| argenx SE | -- |
| Arcutis Biotherapeutics, Inc. | 15.01M |
| Damora Therapeutics, Inc. | -31.17M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.701M |
| Total Expenses (Quarterly) | 67.84M |
| EPS Diluted (Quarterly) | -0.5199 |
| Enterprise Value | 2.581B |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | -1.73K% |
| Earnings Yield | -7.96% |
| Normalized Earnings Yield | -7.139 |